Xfund is among the backers of a $17m round for ImmuneID, which has been set up to commercialise research from Harvard University and Johns Hopkins University.
ImmuneID, a US-based precision immunology company based on Harvard University and Johns Hopkins University research, has launched with $17m in funding from investors including Harvard-aligned venture capital firm Xfund.
Longwood Fund led the round, which also included Arch Venture Partners, Pitango HealthTech and In-Q-Tel, the investment affiliate of the US intelligence community, as well as unnamed investors.
ImmuneID is working on a platform that exploits sequencing, robotic automation and artificial intelligence to identify treatments for conditions linked…
